A retrospective cohort study of the intermediate and long-term outcomes of dual biologics for patients with medically refractory inflammatory bowel disease (IBD).

This study is a retrospective review of clinical data for patients with medically refractory IBD managed with dual biologics. The data reviewed will pertain to type of dual biologics, rates of remission and adverse outcomes.